31 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22620 | any line, RECIST 1.1 | Ahmad Hussein Awada | Multiple | Boehringer Ingelheim | 1367.1 | Trial closed | An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22632 | any line, RECIST 1.1 | Philippe Aftimos | Multiple | Amcure GmbH | AMC303-01 | Trial closed | A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin | philippe.aftimos@hubruxelles.be | 1/1b | 1 | |
| 22732 | Locally-advanced or metastatic malignancy with : KRAS p.G12Cmutation | Nuria Kotecki | Multiple | Amgen | AMG510 | Trial closed for recruitment | A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation | Nuria.Kotecki@hubruxelles.be | 1/2 | 1 | |
| 22649 | Non metastatic urothelial carcinoma candidate for surgery Cisplatin eligible and ineligible |
Thierry Gil | Ureters - bladder - urethra | Institut Jules Bordet | AURA | Trial closed for recruitment | Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers | thierry.gil@hubruxelles.be | 2 | 2 | |
| 22832 | 2 or 3 prior regimens, including one with VEGFR TKI | Nieves Martinez Chanza | Kidney cells carcinoma | Aveo Oncology | AV-951-15-303 | Trial closed | A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma | nieves.martinez-chanza@hubruxelles.be | 3 | 3 | |
| 28690 | Nieves Martinez Chanza | prostate | AstraZeneca | CAPItello-281 | Trial closed for recruitment | A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) | nieves.martinez-chanza@hubruxelles.be | 3 | 3 | ||
| 22639 | First line metastatic | Spyridon Sideris | Kidney | Eisai Limited | CLEAR | Trial closed for recruitment | A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR) | spyridon.sideris@hubruxelles.be | 3 | 3 | |
| 22829 | No prior exposure to immune-mediated therapy | Thierry Gil | Bladder | AstraZeneca | DANUBE | Trial closed | A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer | thierry.gil@hubruxelles.be | 3 | 3 | |
| 22692 | any line / Lung metastasis | Konstantinos Stathopoulos | Lung | EORTC | EORTC 1658 | Trial closed | Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) | konstantinos.stathopoulos@hubruxelles.be | |||
| 22729 | Progression or relapse with anti-PD1 or anti-PD-L1 and platinum-based chemotherapy for locally advanced or metastatic urothelial carcinoma. | Nieves Martinez Chanza | Ureters - bladder - urethra | Astellas | EV-301 | Trial closed for recruitment | An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | nieves.martinez-chanza@hubruxelles.be | 3 | 3 | |
| 22798 | Relasped/refractory patient | Christiane Jungels | Multiple | Imcheck | EVICTION | Trial open for recruitment | A fist-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an Immune Checkpoint Inhibitor, in patients with advanced-stage, relapsed/refractory cancer | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 22764 | any line | Ahmad Hussein Awada | Multiple | Genentech-Roche | GO29674 | Trial closed | A Phase Ib, Open-Label, Dose-escalation Study of the safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients with Locally Advanced or Metastatic Solid Tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22625 | RECIST 1.1, after standard trerapy | Ahmad Hussein Awada | Multiple | Lilly | I7W-MC-JQBA | Trial closed | A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22654 | "Adjuvant", healthy margin | Spyridon Sideris | Kidney | BMS - Bristol Myers Squibb int. | IJB_2691 | Trial closed for recruitment | Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse | spyridon.sideris@hubruxelles.be | 3 | 3 |